Results 111 to 120 of about 30,793 (265)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
, 2020 As tumors grow, they acquire mutations, some of which create neoantigens that influence the response of patients to immune checkpoint inhibitors. We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity.
Teresa Marafioti (7741250) +35 more
core
Medicinal Research Reviews, EarlyView.ABSTRACT Targeted elimination of pathogenic proteins remains a fundamental challenge in therapeutic intervention, particularly for proteins considered “undruggable” by conventional inhibition‐based approaches. Aptamer–based targeted protein degradation (TPD) has emerged as a versatile strategy that leverages the high specificity, structural ...
Ambrin Malik +3 more
wiley +1 more source
Cancer immunotherapy targeting neoantigens
Seminars in Immunology, 2016 Neoantigens are antigens encoded by tumor-specific mutated genes. Studies in the past few years have suggested a key role for neoantigens in cancer immunotherapy. Here we review the discoveries of neoantigens in the past two decades and the current advances in neoantigen identification.
Lu, Yong-Chen, Robbins, Paul F.
openaire +2 more sources
Modalities to identify clinically actionable neoantigens
Immune checkpoint inhibitors (ICIs), which restore antitumor immunity mediated by T cells, have caused a paradigm shift in cancer therapy. However, only a subset of patients achieve durable clinical responses, highlighting the need to better understand ...
Yosuke Togashi, Takamasa Ishino
core +1 more source
The Journal of Pathology, EarlyView.Abstract Pretreatment prediction of neoadjuvant response remains an unresolved challenge in locally advanced rectal cancer, where management is moving towards risk‐adapted and response‐oriented treatment strategies. Prediction remains difficult because response reflects interacting tumour‐intrinsic, immune, stromal, and spatial processes that are ...
Gina F Boot +17 more
wiley +1 more source
Neoantigen prioritization based on antigen processing and presentation
Frontiers in ImmunologySomatic mutations in tumor cells give rise to mutant proteins, fragments of which are often presented by MHC and serve as neoantigens. Neoantigens are tumor-specific and not expressed in healthy tissues, making them attractive targets for T-cell-based ...
Serina Tokita +4 more
doaj +1 more source
Precision Medical Sciences, EarlyView.The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan +3 more
wiley +1 more source
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan +2 more
wiley +1 more source
Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia
Asia-Pacific Journal of Clinical Oncology, EarlyView.Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski +6 more
wiley +1 more source
, 2017 Cancer immunotherapy has recently emerged as a powerful tool for the treatment of diverse advanced malignancies. In particular, therapeutic application of immune checkpoint modulators, such as anti-CTLA4 or anti-PD-1/PD-L1 antibodies, have shown efficacy
Bräunlein, Eva;Krackhardt, Angela M +1 more
core +1 more source